Schroder Investment Management Group Increases Stock Holdings in Abbott Laboratories $ABT

Schroder Investment Management Group boosted its stake in Abbott Laboratories (NYSE:ABT) by 10.3% in the third quarter, Holdings Channel reports. The fund owned 1,256,689 shares of the healthcare product maker’s stock after buying an additional 117,386 shares during the quarter. Schroder Investment Management Group’s holdings in Abbott Laboratories were worth $168,321,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the 3rd quarter worth $31,000. Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last ninety days. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 2.9%

NYSE:ABT opened at $112.69 on Tuesday. The company has a market cap of $195.82 billion, a PE ratio of 30.29, a P/E/G ratio of 1.74 and a beta of 0.74. The business’s 50 day moving average is $115.86 and its two-hundred day moving average is $124.44. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.15.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Citigroup cut their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Daiwa Securities Group decreased their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Piper Sandler dropped their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday, January 23rd. Finally, Oppenheimer cut their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.37.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.